2026 Interim Report
Filed with HKEX · Stock code 7630 · · 61 pages · English
Summary by 6ix AI
The report indicates significant revenue growth compared to the same period last year, alongside a decrease in losses. It also outlines advancements in the company's drug pipeline, including partnerships and product developments. The report emphasizes the commercialization of senaparib as a first-line therapy for ovarian cancer in China.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
IMPACT Therapeutics, Inc. on 6ix
Earlier from IMPACT Therapeutics
- IMPACT Therapeutics Signs Exclusive License Agreement with Pharmanovia for Senaparib in Europe, Middle East and North Africa, Australia and New Zealand
- Articles of association
- Next Day Disclosure Return
Later from IMPACT Therapeutics
- Voluntary announcement - positive CHMP opinion for senaparib, as potential first-line maintenance treatment of advanced epithelial ovarian, fallopian tube, and primary peritoneal cancer
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
- Voluntary announcement - poster presentation of latest clinical data for senaparib and PARP1-selective inhibitors IMP1734 and IMP1707 at 2026 ESMO congress
- Voluntary announcement - on-market share repurchase
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2026
Follow IMPACT Therapeutics into a list and get an email when it puts out news.
Follow IMPACT Therapeutics